Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03086200 · ClinicalTrials.gov registry record · NA
Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals
A NA study, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 263
- Enrollment target
NCT03086200: Completed NA study, sponsored by University of California, San Diego.
NCT03086200 is a NA study that has completed, run by University of California, San Diego. The registered enrollment target is 263 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03086200, a NA study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 263 participants
- Enrollment target
Study Summary
CCTG 603 is an open-label, two-arm, randomized (1:1) clinical demonstration project to determine if brief Motivational Interviewing (MI-B) added to a text-message based adherence intervention (iTAB) improves adherence to PrEP among transgender persons.
Primary Outcome
To compare adherence to fixed dose TDF/FTC, as measured by intracellular levels of TFV-DP \> 1246 fmol/punch, between subjects randomized to receive iTAB with versus without brief Motivational Interviewing, when used for adherence support to pre-exposure prophylaxis among transgender individuals at elevated risk for HIV acquisition.
Interventions
- BEHAVIORAL brief Motivational Interviewing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 263 participants |
| Start Date | 2017-06-23 |
| Est. Completion | 2020-12-18 |
| Phase | NA |
What the finished NCT03086200 record still lists
NCT03086200 is an interventional study that assigns participants to a tested intervention. The registered 263 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 1 intervention - of which brief Motivational Interviewing is the first listed.
NCT03086200 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03086200 about?
NCT03086200 is a clinical study titled "Randomized Controlled Trial of iTAB Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals". CCTG 603 is an open-label, two-arm, randomized (1:1) clinical demonstration project to determine if brief Motivational Interviewing (MI-B) added to a text-message based adherence intervention (iTAB) improves adherence to PrEP among transgender persons.
What is the current status of trial NCT03086200?
This trial is currently completed. It is a NA study. The enrollment target is 263 participants. The study started on 2017-06-23. Estimated completion is 2020-12-18.
What interventions are being tested in trial NCT03086200?
The interventions under investigation include: brief Motivational Interviewing (BEHAVIORAL).
Who is sponsoring clinical trial NCT03086200?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03086200's enrollment target sits among peer trials
263 396th of 2000 higher than 1,604 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04067336 · 263 participants · Phase 1
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
- NCT06234423 · 263 participants · Phase 1
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
- NCT06724627 · 263 participants · NA
Application of the Belle.AI Dermatological Image Reference System for Patient Diagnosis in an Active Clinical Setting
- NCT04101669 · 264 participants · NA
RESET System Pivotal Trial (Rev F)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI